Sugi Predict

Sugi Predict / Compounds / SCHEMBL3522095

SCHEMBL3522095

SCHEMBL3522095

O=C(O)c1cc(-c2ccccn2)no1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.54
▸ KDM6B O15054 1/20 0.54
▸ KDM4A O75164 1/20 0.54
▸ KDM5C P41229 1/20 0.54
▸ KDM4C Q9H3R0 1/20 0.54
▸ KDM2A Q9Y2K7 1/20 0.54
▸ KDM3A Q9Y4C1 1/20 0.54
▸ PIN1 Q13526 1/20 0.50
▸ USP30 Q70CQ3 1/20 0.48
▸ PTPN1 P18031 2/20 0.47
▸ LMNA P02545 4/20 0.47
▸ P4HTM Q9NXG6 2/20 0.47
▸ CCR1 P32246 2/20 0.47
▸ CCR5 P51681 2/20 0.47
▸ CCR8 P51685 2/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ METAP1 P53582 1/20 0.47
▸ BLM P54132 1/20 0.47
▸ HIF1A Q16665 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31039822 1.00 KDM4E (0.54) KDM4EKDM6BKDM4AKDM5CKDM4C
SCHEMBL31434603 0.81 USP30 (0.47) KDM4EKDM6BKDM4AKDM5CKDM4C
SCHEMBL5287561 0.81 USP30 (0.47) KDM4EKDM6BKDM4AKDM5CKDM4C
SCHEMBL11600197 0.81 HCAR2 (0.48) KDM4EPTPN1CYP1A2SMN1; SMN2RAB9A
SCHEMBL12571307 0.81 HCAR2 (0.48) KDM4EKDM6BKDM4AKDM5CKDM4C
Water SCHEMBL11602658 0.79 HCAR2 (0.47) KDM4EPTPN1CYP1A2SMN1; SMN2RAB9A
Water SCHEMBL11600844 0.79 HCAR2 (0.47) KDM4EPTPN1CYP1A2SMN1; SMN2RAB9A
SCHEMBL212382 0.79 RAB9A (0.68) KDM4EPTPN1CYP1A2SMN1; SMN2RAB9A
SCHEMBL16229246 0.79 HCAR2 (0.43) PTPN1SMN1; SMN2RAB9AHCAR2SCD
SCHEMBL12571308 0.79 HCAR2 (0.43) KDM4EPTPN1CYP1A2SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12325702-B2 ATF6 inhibitors and uses thereof ALTOS LABS, INC. (US) 2025-06-10 — — US disclosed
US-20240124434-A1 ATF6 INHIBITORS AND USES THEREOF ALTOS LABS, INC. 2024-04-18 — — US disclosed
US-20220204495-A1 INHIBITING TRABID Valo Health, LLC 2022-06-30 — — US disclosed
US-20220204495-A1 INHIBITING TRABID Valo Health, LLC 2022-06-30 — — US disclosed
US-20210221803-A1 ATF6 INHIBITORS AND USES THEREOF ALTOS LABS, INC. 2021-07-22 — — US disclosed
US-20210221803-A1 ATF6 INHIBITORS AND USES THEREOF ALTOS LABS, INC. 2021-07-22 — — US disclosed
EP-3774782-A2 ATF6 INHIBITORS AND USES THEREOF Black Belt TX Ltd (GB) 2021-02-17 — — EP disclosed
CN-112313224-A ATF6 inhibitors and uses thereof 黑带医疗有限责任公司 2021-02-02 — — CN disclosed
WO-2020227168-A1 INHIBITING TRABID INTEGRAL EARLY DISCOVERY, INC. (US) 2020-11-12 — — WO disclosed
US-10829485-B2 ATF6 inhibitors and uses thereof BLACK BELT TX LTD (GB) 2020-11-10 — — US disclosed
US-7960544-B2 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-14 — — US disclosed
US-20100197708-A1 INDOLE COMPOUNDS WELLS FARGO BANK, NATIONAL ASSOCIATION 2010-08-05 — — US disclosed
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 — — US disclosed
US-20090264653-A1 USEFUL INDOLE COMPOUNDS IRONWOOD PHARMACEUTICALS, INC. 2009-10-22 — — US disclosed
US-20090118503-A1 FAAH INHIBITORS IRONWOOD PHARMACEUTICALS, INC. 2009-05-07 — — US disclosed
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 — — WO disclosed
US-20060229336-A1 Ccr5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORPORATION 2006-10-12 — — US disclosed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 — — US disclosed
EP-1569646-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-07 — — EP disclosed
WO-2004054974-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124434-A1 ATF6 INHIBITORS AND USES THEREOF ATF4, XBP1, ATF1 KDM4E 4305/4885KDM6B 4027/4885KDM4A 4328/4885
US-12325702-B2 ATF6 inhibitors and uses thereof ATF4, XBP1, ATF1 KDM4E 4305/4885KDM6B 4027/4885KDM4A 4328/4885
US-10829485-B2 ATF6 inhibitors and uses thereof ATF4, XBP1, ATF1 KDM4E 4305/4885KDM6B 4027/4885KDM4A 4328/4885
US-20210221803-A1 ATF6 INHIBITORS AND USES THEREOF ATF4, XBP1, ATF1 KDM4E 4305/4885KDM6B 4027/4885KDM4A 4328/4885
US-20220204495-A1 INHIBITING TRABID TPO, PRKACG, NFKBIA KDM4E 4133/4885KDM6B 3414/4885KDM4A 4306/4885
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 KDM4E 4305/4885KDM6B 3084/4885KDM4A 4225/4885
US-20100197708-A1 INDOLE COMPOUNDS IDO1, IDO2, TPH2 KDM4E 2243/4885KDM6B 2195/4885KDM4A 1992/4885
US-20090264653-A1 USEFUL INDOLE COMPOUNDS FAAH, FAAH2, AANAT KDM4E 2232/4885KDM6B 1085/4885KDM4A 1795/4885
US-20060229336-A1 Ccr5 antagonists as therapeutic agents CCR5, CCR1, CXCR3 KDM4E 4644/4885KDM6B 4680/4885KDM4A 4735/4885
US-20090118503-A1 FAAH INHIBITORS FAAH, FAAH2, CNR2 KDM4E 1921/4885KDM6B 1722/4885KDM4A 1769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.